• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by QuidelOrtho Corporation

    7/9/25 4:12:22 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $QDEL alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 2)


    QuidelOrtho Corporation

    (Name of Issuer)


    Common Stock, par value $0.001 per share

    (Title of Class of Securities)


    219798105

    (CUSIP Number)


    06/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    219798105


    1Names of Reporting Persons

    Rubric Capital Management LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,637,738.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,637,738.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,637,738.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.86 %
    12Type of Reporting Person (See Instructions)

    IA, PN


    SCHEDULE 13G

    CUSIP No.
    219798105


    1Names of Reporting Persons

    David Rosen
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,637,738.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,637,738.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,637,738.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.86 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    QuidelOrtho Corporation
    (b)Address of issuer's principal executive offices:

    9975 Summers Ridge Road San Diego, CA, 92121
    Item 2. 
    (a)Name of person filing:

    This statement is filed by: (i) Rubric Capital Management LP ("Rubric Capital"), the investment adviser to certain investment funds and/or accounts (collectively, the "Rubric Funds") that hold the shares of common stock, par value $0.001 (the "Common Stock") of QuidelOrtho Corporation, a Delaware corporation (the "Issuer") reported herein; and (ii) David Rosen ("Mr. Rosen"), Managing Member of Rubric Capital Management GP LLC, the general partner of Rubric Capital The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons." The filing of this statement should not be construed as an admission that any of the forgoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the Shares reported herein.
    (b)Address or principal business office or, if none, residence:

    The address of the principal business office of each of the Reporting Persons is 155 East 44th St, Suite 1630, New York, NY 10017.
    (c)Citizenship:

    Rubric Capital is a Delaware limited partnership. Mr. Rosen is a citizen of the United States of America.
    (d)Title of class of securities:

    Common Stock, par value $0.001 per share
    (e)CUSIP No.:

    219798105
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The percentage set forth in Row (11) of the cover page for each of the Reporting Persons and in Item 4(b) is based on the 67,625,872 shares of Common Stock outstanding as of April 30, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended March 30, 2025 filed with the Securities and xchange Commission on May 8, 2025.
    (b)Percent of class:

    6.86  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference.

     (ii) Shared power to vote or to direct the vote:

    The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference.

     (iii) Sole power to dispose or to direct the disposition of:

    The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference.

     (iv) Shared power to dispose or to direct the disposition of:

    The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    See Item 2(a). Rubric Capital Master Fund LP, a Rubric Fund, has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, more than 5% of the Common Stock.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Rubric Capital Management LP
     
    Signature:/s/ Michael Nachmani
    Name/Title:Michael Nachmani / Chief Operating Officer
    Date:07/09/2025
     
    David Rosen
     
    Signature:/s/ David Rosen
    Name/Title:David Rosen / Individually
    Date:07/09/2025
    Get the next $QDEL alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $QDEL

    DatePrice TargetRatingAnalyst
    5/8/2025$44.00Hold → Buy
    Jefferies
    12/11/2024$44.00 → $50.00Neutral → Buy
    Citigroup
    12/10/2024$43.00Hold
    Jefferies
    9/19/2024$42.00 → $50.00Neutral
    UBS
    9/5/2024$40.00 → $57.00Hold → Buy
    Craig Hallum
    3/4/2024$70.00 → $42.00Neutral → Sell
    UBS
    2/14/2024$66.00 → $37.00Neutral → Underweight
    JP Morgan
    12/11/2023$95.00 → $72.00Buy → Neutral
    Citigroup
    More analyst ratings

    $QDEL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Buechler Kenneth F exercised 9,215 shares at a strike of $15.74, increasing direct ownership by 10% to 101,921 units (SEC Form 4)

    4 - QuidelOrtho Corp (0001906324) (Issuer)

    7/17/25 4:09:04 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Chief Legal Officer Hodges Michelle A was granted 11,873 shares and covered exercise/tax liability with 6,030 shares, increasing direct ownership by 25% to 29,212 units (SEC Form 4)

    4 - QuidelOrtho Corp (0001906324) (Issuer)

    7/2/25 4:10:58 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Chief Financial Officer Busky Joseph M. was granted 21,367 shares and covered exercise/tax liability with 9,883 shares, increasing direct ownership by 58% to 31,427 units (SEC Form 4)

    4 - QuidelOrtho Corp (0001906324) (Issuer)

    7/2/25 4:08:51 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $QDEL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    QuidelOrtho upgraded by Jefferies with a new price target

    Jefferies upgraded QuidelOrtho from Hold to Buy and set a new price target of $44.00

    5/8/25 9:44:58 AM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    QuidelOrtho upgraded by Citigroup with a new price target

    Citigroup upgraded QuidelOrtho from Neutral to Buy and set a new price target of $50.00 from $44.00 previously

    12/11/24 8:21:07 AM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Jefferies initiated coverage on QuidelOrtho with a new price target

    Jefferies initiated coverage of QuidelOrtho with a rating of Hold and set a new price target of $43.00

    12/10/24 8:01:07 AM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $QDEL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Blaser Brian J. bought $249,878 worth of shares (6,033 units at $41.42) (SEC Form 4)

    4 - QuidelOrtho Corp (0001906324) (Issuer)

    12/13/24 4:12:57 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Busky Joseph M bought $99,663 worth of shares (2,150 units at $46.35) (SEC Form 4)

    4 - QuidelOrtho Corp (0001906324) (Issuer)

    2/26/24 6:48:23 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $QDEL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    QuidelOrtho Completes Debt Refinancing

    SAN DIEGO, Aug. 21, 2025 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced the completion of a series of related transactions to refinance its debt structure and support future growth. Through these transactions, the Company extended its debt maturities and reduced required amortization payments. Summary of New Transactions: $1.15 billion 5-year senior secured Term Loan A, which repla

    8/21/25 4:30:00 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Science Bytes Podcast Explores How Diagnostics Can Help Protect Students and Communities

    SAN DIEGO, Aug. 21, 2025 /PRNewswire/ -- With classrooms once again filled and respiratory virus season beginning, QuidelOrtho Corporation (NASDAQ:QDEL), a global leader of in vitro diagnostics, is sharing timely public health insights from Dr. Jonathan Temte, Professor of Family Medicine and Community Health at the University of Wisconsin-Madison. In this 50th episode of QuidelOrtho Science Bytes, Dr. Temte outlines the seasonal challenges posed by influenza, RSV, COVID-19 and vaccine-preventable diseases such as measles and whooping cough. He emphasizes that early detection

    8/21/25 9:00:00 AM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    QuidelOrtho Welcomes Erich Wolff as Executive Vice President, Strategy & Corporate Development

    SAN DIEGO, Aug. 19, 2025 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global leader of in vitro diagnostics, welcomes Erich Wolff as Executive Vice President, Strategy & Corporate Development. In this role, Mr. Wolff will report directly to President and Chief Executive Officer Brian Blaser, and he will lead the Company's enterprise strategy, business development, government affairs and portfolio management functions. Mr. Wolff brings over two decades of leadership experience in strategy, M&A and business development across the heal

    8/19/25 4:05:00 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $QDEL
    SEC Filings

    View All

    QuidelOrtho Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation

    8-K - QuidelOrtho Corp (0001906324) (Filer)

    8/21/25 4:35:40 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by QuidelOrtho Corporation

    SCHEDULE 13G/A - QuidelOrtho Corp (0001906324) (Subject)

    8/7/25 3:58:39 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    QuidelOrtho Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - QuidelOrtho Corp (0001906324) (Filer)

    8/5/25 4:11:59 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $QDEL
    Leadership Updates

    Live Leadership Updates

    View All

    QuidelOrtho Welcomes Erich Wolff as Executive Vice President, Strategy & Corporate Development

    SAN DIEGO, Aug. 19, 2025 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global leader of in vitro diagnostics, welcomes Erich Wolff as Executive Vice President, Strategy & Corporate Development. In this role, Mr. Wolff will report directly to President and Chief Executive Officer Brian Blaser, and he will lead the Company's enterprise strategy, business development, government affairs and portfolio management functions. Mr. Wolff brings over two decades of leadership experience in strategy, M&A and business development across the heal

    8/19/25 4:05:00 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    QuidelOrtho Announces Appointment of Two Independent Directors to its Board

    Veteran Healthcare CEOs John R. Chiminski and R. Scott Huennekens Bring Deep Industry Experience, Operational Expertise and Financial Acumen to the QuidelOrtho Board QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced the appointments of John R. Chiminski and R. Scott Huennekens to its board of directors (the "Board"), effective December 6, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241210769572/en/R. Scott Huennekens (Photo: Business Wire) T

    12/10/24 7:00:00 AM ET
    $CTLT
    $HYPR
    $NVST
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Medical/Dental Instruments

    QuidelOrtho Announces New R&D Executive Leader

    Jonathan Siegrist appointed as EVP of R&D and CTO QuidelOrtho Corporation (NASDAQ:QDEL), a global leader in innovative diagnostic solutions, is pleased to announce the appointment of Jonathan Siegrist, PhD, as its new Executive Vice President of Research and Development (R&D) and Chief Technology Officer (CTO), effective as of October 7, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241009251239/en/Jonathan Siegrist, EVP of R&D and CTO, QuidelOrtho (Photo: Business Wire) Siegrist brings a wealth of industry expertise and leadership experience with over 15 years in molecular diagnostics, microfluidic platforms, and biomedi

    10/9/24 7:00:00 AM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $QDEL
    Financials

    Live finance-specific insights

    View All

    QuidelOrtho Reports Second Quarter 2025 Financial Results

    ― Labs revenue grew 4% as reported and 5% in constant currency ―― Adjusted EBITDA margin improved by 330 basis points; Achieved $100 million annualized cost savings from initiatives announced in 2024 ― ― Company reiterates full-year 2025 financial guidance ― Second Quarter 2025 Results(all comparisons are to the prior year period) Total revenue was $614 million, as reportedNon-respiratory revenue was $567 million, a decrease of 2% both as reported and in constant currency; excluding Donor Screening, non-respiratory revenue grew 1% in constant currencyLabs revenue grew 4% as reported and 5% in constant currencyImmunohematology revenue grew 4% as reported and 3% in constant currencyRespiratory

    8/5/25 4:10:00 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    QuidelOrtho to Report Second Quarter 2025 Financial Results

    SAN DIEGO, July 22, 2025 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that it will report its financial results for its second quarter 2025 ended June 29, 2025, after the market close on Tuesday, August 5, 2025. Following the release of financial results, QuidelOrtho will hold a conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET to discuss its financial results. Interested

    7/22/25 4:30:00 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    QuidelOrtho Announces Strategy to Accelerate Growth in Molecular Diagnostics

    ―Company Intends to Acquire LEX Diagnostics Upon U.S. FDA Clearance――Company Plans to Discontinue Savanna® Platform Development――Company Reaffirms Full Year 2025 Financial Guidance ――Company to Host Conference Call Today at 5:00 p.m. ET― SAN DIEGO, June 3, 2025 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs, and transfusion medicine, today announced a refocusing of its molecular diagnostics strategy. This strategy includes the intent to acquire full ownership of LEX Diagnostics after 510(k) clearance by the U.S. Food and Drug Administrat

    6/3/25 4:10:00 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $QDEL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by QuidelOrtho Corporation

    SC 13G/A - QuidelOrtho Corp (0001906324) (Subject)

    12/6/24 10:11:24 AM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: SEC Form SC 13D/A filed by QuidelOrtho Corporation

    SC 13D/A - QuidelOrtho Corp (0001906324) (Subject)

    11/21/24 5:10:19 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: SEC Form SC 13G/A filed by QuidelOrtho Corporation

    SC 13G/A - QuidelOrtho Corp (0001906324) (Subject)

    11/14/24 1:28:35 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care